Advances in the pharmacotherapeutic options for primary nodal peripheral T-cell lymphoma
- 13 June 2021
- journal article
- review article
- Published by Informa UK Limited in Expert Opinion on Pharmacotherapy
- Vol. 22 (9), 1203-1215
- https://doi.org/10.1080/14656566.2021.1882997
Abstract
Introduction Peripheral T cell lymphomas (PTCL) are a group of heterogenous hematologic malignancies derived from post-thymic T lymphocytes and mature NK cells. Conventional chemotherapy does not guarantee a good outcome. Areas covered The article summarizes recent investigational therapies and their mechanism of action, as well as the pharmacological properties, clinical activity, and toxicity of new agents in the treatment of primary nodal PTCLs. The review scrutinized papers included in the MEDLINE (PubMed) database between 2010 and October 2020. These were supplemented with a manual search of conference proceedings from the previous five years of the American Society of Hematology, European Hematology Association, and American Society of Clinical Oncology. Further relevant publications were obtained by reviewing the references from the chosen articles. Expert opinion PTCLs have proved difficult to treat and investigate because of their rarity. Studies of aggressive lymphoma, including a small proportion of T-cell lymphomas, found that any benefit from intensified traditional chemotherapy in patients with PTCL is accompanied by increased toxicity. However, the management of PTCL is beginning to change dramatically, thanks to the use of more sophisticated agents targeting the mechanisms of disease development.Keywords
Funding Information
- Medical University of Lodz, Poland
This publication has 99 references indexed in Scilit:
- Up-Front Autologous Stem-Cell Transplantation in Peripheral T-Cell Lymphoma: NLG-T-01Journal of Clinical Oncology, 2012
- Programmed Death Ligand 1 Is Expressed by Non–Hodgkin Lymphomas and Inhibits the Activity of Tumor-Associated T CellsClinical Cancer Research, 2011
- Lenalidomide monotherapy for relapsed/refractory peripheral T-cell lymphoma not otherwise specifiedLeukemia & Lymphoma, 2011
- Pralatrexate in Patients With Relapsed or Refractory Peripheral T-Cell Lymphoma: Results From the Pivotal PROPEL StudyJournal of Clinical Oncology, 2011
- Treatment and prognosis of mature T-cell and NK-cell lymphoma: an analysis of patients with T-cell lymphoma treated in studies of the German High-Grade Non-Hodgkin Lymphoma Study GroupBlood, 2010
- Folotyn (Pralatrexate Injection) for the Treatment of Patients with Relapsed or Refractory Peripheral T-Cell Lymphoma: U.S. Food and Drug Administration Drug Approval SummaryClinical Cancer Research, 2010
- Comparison of four prognostic scores in peripheral T-cell lymphomaAnnals Of Oncology, 2010
- Clinical Trials for Human T-Cell Lymphotropic Virus Type I–Associated Peripheral T-Cell Lymphoma in JapanSeminars in Hematology, 2010
- Overexpression of Syk tyrosine kinase in peripheral T-cell lymphomasLeukemia, 2008
- Novel t(5;9)(q33;q22) fuses ITK to SYK in unspecified peripheral T-cell lymphomaLeukemia, 2005